IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle
By Tom Wilbur | August 6, 2019
Patents are unique in that they are a form of IP protection established in the U.S. Constitution that grants inventors the right to their inventions without others being able to make, use or sell...
Read More
IP Explained: Understanding biopharmaceutical innovation
By Andrew Powaleny | July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...
Read More
IP Explained: What is Section 101 and why reforms are needed
By Tom Wilbur | June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...
Read More
IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry
By Tom Wilbur | May 2, 2019
Strong patent protections are fundamental to the creation of new treatments and cures that extend and improve patients’ lives. In recent years, critics of the biopharmaceutical industry have...
Read More
IP Explained: Why patents are so critical to biopharmaceutical innovation
By Tom Wilbur | April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...
Read More
Special 301 submission calls for a level playing field for American innovators
By Megan Van Etten | March 13, 2019
The Office of the U.S. Trade Representative (USTR)’s 2019 Special 301 Report – scheduled to be released this spring – brings critical attention to overseas intellectual property (IP) and market...
Read More
Celebrating U.S. innovation as USPTO issues the 10 millionth patent
By Nicole Longo | June 19, 2018
The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for...
Read More
Supreme Court decisions in two cases pave way for IPR reforms
By Nicole Longo | May 31, 2018
At the end of April, the Supreme Court decided two cases concerning the inter partes review (IPR) proceedings enacted as part of the 2011 America Invents Act (AIA). While distinct cases, together...
Read More
What is inter partes review and why does it matter?
By Nicole Longo | March 16, 2018
For more than three decades Hatch-Waxman (the Drug Price Competition and Patent Term Restoration Act of 1984) has encouraged innovation in biopharmaceutical development while at the same time...
Read More
ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation
By Mark Grayson | May 5, 2017
America’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property...
Read More
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
